Almost one billion people worldwide have high blood pressure, including 38 percent of people in the UK. Traditional treatment methods of diet, exercise and medication are often unable to help patients reach their lower blood pressure goals. Left untreated, high blood pressure may lead to heart attack, stroke and kidney or heart failure.
"RESPeRATE complements well our existing pharmacy product offerings for hypertensives within the UK. We hope to add real value to the independent pharmacist and the patients they serve by providing a comprehensive approach for hypertension management," said Jay Mashru, director, Mashco.
RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.
About InterCure, Ltd.
InterCure, a medical device company, publicly traded on the Tel-Aviv
Stock Exchange (TASE: INCR) has become a leader in the growing Personal
Therapeutic Device category. Its broadly patented "device-guided breathing"
technology platform enables a systematic reduction in sympathetic outflow
of the autonomic nervous system. InterCure is successfully selling the
world's first hypertension treatment device, RESPeRATE
|SOURCE InterCure, Ltd.|
Copyright©2007 PR Newswire.
All rights reserved